

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF Art Unit: 1634
Lane, Roger Michael et al. Examiner: Pohnert, Steven C
INTERNATIONAL APPLICATION NO: PCT/EP03/08719
FILED: August 06, 2003
U.S. APPLICATION NO: 10/523047
35 USC §371 DATE: November 08, 2005
FOR: Methods for the Treatment of Dementia Based on Apo e Genotype

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

☒ supplemental to the Information Disclosure Statements filed November 8, 2005, and September 13, 2007.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis.

☒ This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c) or 37 C.F.R. §1.97(d).

☒ A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the



Copies of the non-asterisked references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Daniel Woods
Attorney for Applicant
Reg. No. 59,864

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-9587

Date: